financetom
Business
financetom
/
Business
/
Match Group's Tinder Grapples With Declining 'a la Carte' Trends, Weak Monetization, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Match Group's Tinder Grapples With Declining 'a la Carte' Trends, Weak Monetization, Morgan Stanley Says
May 9, 2024 9:52 AM

12:21 PM EDT, 05/09/2024 (MT Newswires) -- Match Group's ( MTCH ) Tinder faces increasing challenges with declining "a la carte" trends and below-par monetization, resulting in minimal revenue growth for the remainder of the year, Morgan Stanley said in a note Thursday.

Tinder expects only minimal revenue growth with low single digit percentages throughout 2024, while Q3 net additions remain positive sequentially, they appear weaker compared to the same period last year, Morgan Stanley said, adding that "We believe Tinder sacrificing some short-term financials to try and reaccelerate user growth is the right strategic move, but it does further question [near-term] growth."

On the other hand, the company's dating app Hinge continues "to be a bright spot," demonstrating a robust 50% year-over-year revenue growth, showcasing that growth opportunities persist when a brand aligns closely with its target market, the note said.

Despite Tinder's challenges, the overall portfolio maintains a stable margin profile, highlighting the flexibility in cost management enabled by the diversified portfolio approach, Morgan Stanley said.

Morgan Stanley maintained its equalweight rating on Match Group ( MTCH ) and lowered its price target to $34 from $37.

Price: 30.35, Change: +0.53, Percent Change: +1.78

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study
Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study
Aug 26, 2025
07:54 AM EDT, 08/26/2025 (MT Newswires) -- Marker Therapeutics ( MRKR ) said Tuesday its investigational therapy MT-601 achieved a 66% objective response rate in patients with relapsed non-Hodgkin lymphoma, and 50% showed a complete response. In the phase 1 study, eight out of 12 non-Hodgkin lymphoma patients responded to treatment, including six with complete responses, Marker Therapeutics ( MRKR...
Singapore's Keppel files for $53 million claim against Seatrium over Brazil corruption case
Singapore's Keppel files for $53 million claim against Seatrium over Brazil corruption case
Aug 26, 2025
(Reuters) -Singapore's Keppel has initiated arbitration proceedings against local shipbuilder Seatrium for a S$68.4 million ($53.33 million) claim related to a corruption crackdown in Brazil, the companies said on Tuesday. In 2022, Seatrium had made provisions worth S$82.4 million to pay Keppel against claims related to the crackdown, named Operation Car Wash. Seatrium noted the obligation to pay Keppel expired...
Spotify Adding In-App Messaging Feature
Spotify Adding In-App Messaging Feature
Aug 26, 2025
07:51 AM EDT, 08/26/2025 (MT Newswires) -- Spotify Technology ( SPOT ) said Tuesday it is launching an in-app messaging feature that allows users to start one-on-one conversations and share content directly within the platform. Users can accept or reject message requests, Spotify ( SPOT ) said and added that conversations will be secured with encryption both in transit and...
Regeneron Says Cemdisiran Monotherapy Meets Primary, Key Secondary Endpoints in Late-Stage Trial in Generalized Myasthenia Gravis Patients
Regeneron Says Cemdisiran Monotherapy Meets Primary, Key Secondary Endpoints in Late-Stage Trial in Generalized Myasthenia Gravis Patients
Aug 26, 2025
07:54 AM EDT, 08/26/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Tuesday that its investigational cemdisiran monotherapy met the primary and key secondary endpoints in a late-stage trial in adults with generalized myasthenia gravis. The company said Cemdisiran monotherapy showed a 2.3-point placebo-adjusted improvement in MG-ADL total score. Detailed results from the trial will be presented at an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved